Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. filings document the formal record for a Nasdaq-listed precision medicine company focused on transplant testing, patient solutions, digital health technologies, and related diagnostic products. Recent Form 8-K filings furnish operating results, preliminary financial metrics, corporate presentations, and material agreements tied to the planned acquisition of Naveris and the sale of the Lab Products business to Eurobio Scientific.
The company’s regulatory disclosures also cover capital structure and governance matters, including common stock repurchase authorizations, inducement and equity incentive awards, executive officer changes, bylaw amendments, and shareholder derivative settlement materials. Its proxy statement details director elections, auditor ratification, advisory compensation votes, equity plan amendments, board governance, ownership information, and executive compensation.
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, executed an open-market sale of 2,688 shares of common stock on May 5, 2026 at a weighted average price of 20.6775 per share. After the sale, he directly owned 113,924 shares of CareDx common stock. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan, which had been adopted on September 4, 2025, and the sale prices ranged from 20.405 to 21.26 per share.
CareDx, Inc. reported a routine insider tax-related transaction by its Secretary and General Counsel, Jeffrey Adam Novack. On May 1, 2026, 2,873 shares of common stock were withheld by the company at $21.50 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Novack directly held 116,612 shares of CareDx common stock. This was a compensation-related tax-withholding event, not an open-market purchase or sale.
CareDx, Inc. filed an automatic shelf registration on Form S-3 to register an unspecified aggregate amount of common stock, preferred stock, debt securities, warrants, subscription rights and/or units from time to time after this registration statement becomes effective. The shelf prospectus describes broad terms and distribution methods and states that each offering will be detailed in a prospectus supplement.
The prospectus notes 51,274,651 shares of common stock outstanding as of March 31, 2026, authorized capital of 100,000,000 common shares and 10,000,000 preferred shares, and discloses outstanding equity awards and the Nasdaq listing (symbol CDNA).
CareDx, Inc. filed an automatic shelf registration on Form S-3 to register an unspecified aggregate amount of common stock, preferred stock, debt securities, warrants, subscription rights and/or units from time to time after this registration statement becomes effective. The shelf prospectus describes broad terms and distribution methods and states that each offering will be detailed in a prospectus supplement.
The prospectus notes 51,274,651 shares of common stock outstanding as of March 31, 2026, authorized capital of 100,000,000 common shares and 10,000,000 preferred shares, and discloses outstanding equity awards and the Nasdaq listing (symbol CDNA).
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.
CareDx, Inc. is holding its 2026 annual stockholders meeting virtually on June 11, 2026, to vote on key governance and compensation matters. Stockholders will elect five directors, ratify Deloitte & Touche LLP as auditor, approve executive pay on an advisory basis, and choose the frequency of future say‑on‑pay votes, with the Board recommending an annual vote.
They will also vote on amending the 2024 Equity Incentive Plan to increase shares reserved for equity awards. The record date is April 15, 2026, covering 51,547,801 common shares. The Board is majority independent, operates four committees, has stock ownership guidelines for directors and executives, a clawback policy, and paid Deloitte $2.43 million in 2025 audit-related fees.
CareDx, Inc. updated the compensation details for Keith Kennedy, who serves as both Chief Financial Officer and Chief Operating Officer. In recognition of his expanded responsibilities, the board’s Compensation and Human Capital Committee granted him new equity awards.
Kennedy received 24,134 restricted stock units (RSUs), with one-third vesting on April 6, 2027 and the remainder vesting quarterly thereafter, subject to continued service. He was also awarded 24,134 performance-based RSUs (PRSUs), which may vest between 0% and 200% of the target amount based on performance over the 2026 and 2027 periods and additional time-based vesting. These grants are under the company’s 2024 Equity Incentive Plan, and his $613,000 annual base salary and 75% target bonus opportunity remain unchanged.
Kennedy Keith reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. CFO & COO Keith Kennedy received a grant of 24,134 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share. After this award, he directly holds 221,548 shares.
According to the terms, one-third of these RSUs will vest on April 6, 2027. The remaining two-thirds will vest in equal quarterly installments over the next eight quarters, so that all units vest by the third anniversary of April 6, 2027, if his employment continues through each vesting date.